Payment overview · 2025
General Payments
$334.04
12 reported records · 5 companies
Healthcare provider profile · identity verified
Keya Malhotra, MBBS
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · LUBBOCK, TX · NPI 1083927271
Verified facts
What the public records show
CMS Open Payments records show Keya Malhotra, MBBS received $334.04 in general payments during 2025 across 12 reported records.
Sumitomo Pharma America, Inc. accounted for 49.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Trintellix.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $164.05 | 49.1% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $107.59 | 32.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.70 | 8.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.90 | 5.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.80 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $334.04 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $164.05 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $107.59 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 29 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 828 | 228 |
| Gabapentin | Gabapentin | 502 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 490 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 472 | 138 |
| Escitalopram Oxalate | Escitalopram Oxalate | 445 | 115 |
| Tramadol Hcl | Tramadol Hcl | 445 | 85 |
| Losartan Potassium | Losartan Potassium | 443 | 127 |
| Lisinopril | Lisinopril | 440 | 129 |
| Hydrochlorothiazide | Hydrochlorothiazide | 321 | 97 |
| Trazodone Hcl | Trazodone Hcl | 298 | 97 |
| Celecoxib | Celecoxib | 295 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 83 |
| Potassium Chloride | Potassium Chloride | 258 | 77 |
| Pregabalin | Pregabalin | 214 | 59 |
| Omeprazole | Omeprazole | 211 | 64 |
| Alendronate Sodium | Alendronate Sodium | 207 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 201 | 53 |
| Myrbetriq | Mirabegron | 194 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 193 | 45 |
| Sertraline Hcl | Sertraline Hcl | 184 | 48 |
| Montelukast Sodium | Montelukast Sodium | 182 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 180 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 69 |
| Estradiol | Estradiol | 167 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 45 |
| Simvastatin | Simvastatin | 157 | 50 |
| Metformin Hcl | Metformin Hcl | 155 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 154 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 48 |
| Allopurinol | Allopurinol | 144 | 43 |
| Buspirone Hcl | Buspirone Hcl | 142 | 53 |
| Meloxicam | Meloxicam | 142 | 45 |
| Metformin Hcl Er | Metformin Hcl | 137 | 41 |
| Eliquis | Apixaban | 134 | 29 |
| Januvia | Sitagliptin Phosphate | 127 | 34 |
| Mounjaro | Tirzepatide | 127 | 21 |
| Furosemide | Furosemide | 122 | 48 |
| Azelastine Hcl | Azelastine Hcl | 117 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 31 |
| Ozempic | Semaglutide | 110 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 19 |
| Ezetimibe | Ezetimibe | 95 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 28 |
| Propranolol Hcl | Propranolol Hcl | 86 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 85 | 34 |
| Valsartan | Valsartan | 83 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 82 | 21 |
| Farxiga | Dapagliflozin Propanediol | 80 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 25 |
| Ketoconazole | Ketoconazole | 73 | 45 |
| Carvedilol | Carvedilol | 72 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 14 |
| Memantine Hcl | Memantine Hcl | 66 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 20 |
| Synthroid | Levothyroxine Sodium | 64 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 63 | 18 |
| Levofloxacin | Levofloxacin | 57 | 45 |
| Nystatin | Nystatin | 57 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 50 |
| Famotidine | Famotidine | 56 | 16 |
| Ondansetron Odt | Ondansetron | 56 | 35 |
| Atenolol | Atenolol | 55 | 17 |
| Mirtazapine | Mirtazapine | 54 | 16 |
| Donepezil Hcl | Donepezil Hcl | 53 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Linzess | Linaclotide | 43 | 12 |
| Cephalexin | Cephalexin | 42 | 37 |
| Bupropion Hcl | Bupropion Hcl | 40 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 39 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Irbesartan | Irbesartan | 38 | suppressed |
| Mirabegron Er | Mirabegron | 37 | 17 |
| Np Thyroid | Thyroid,pork | 37 | suppressed |
| Telmisartan | Telmisartan | 37 | suppressed |
| Armour Thyroid | Thyroid,pork | 36 | suppressed |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 15 |
| Methocarbamol | Methocarbamol | 34 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | 11 |
| Ramipril | Ramipril | 27 | 11 |
| Azithromycin | Azithromycin | 26 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 12 |
| Gemtesa | Vibegron | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Ciclopirox | Ciclopirox | 20 | 11 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334.04 · 12 records | Sumitomo Pharma America, Inc. | Auvelity, GEMTESA, NURTEC ODT, TRINTELLIX, The Cologuard Plus Collection Kit, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error